FREE


BIOSCITECH BiWeekly Newsletter

1 November 2026

SELECTION FROM THE PAST TWO WEEKS

1 November 1954-2026
Hottest News In Biotech, BioResearch, Pharma, BioHealth
Highly Selected Research Papers & Patents
Best Recommended Events and Studentship.

1 November 1954-2026



Global BIOTECH-PHARMA NEWS



Roche returns to China's ADC powerhouse Hansoh for $15B biobucks pact

A year after their first antibody-drug conjugate (ADC) team-up, Roche has returned to Hansoh Pharmaceutical for a mammoth $15 billion biobucks pact. The latest agreement spans a "broad portfolio of ADC programs," Hansoh explained in an Oct. 19 release. They include two ADCs already in preclinical development at the Chinese biopharma, along with multiple programs focused on targets suggested by Roche but powered by Hansoh's ADC tech. The plan is for Jiangsu-based Hansoh to take these programs through phase 1 trials, before passing over responsibility to Roche to develop the ADCs worldwide—excluding Greater China

https://www.fiercebiotech.com/biotech/roche-returns-chinas-adc-powerhouse-hansoh-15b-biobucks-pact






2026 Scientific Highlights

- **1950RO**. Phase 1b/2a study of LK101, a personalized neoantigen DC vaccine, as first-line maintenance therapy in locally advanced/metastatic NSCLC
- **1951RO.** Efficacy of pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in patients with SCLC or TNBC with brain metastases: a subgroup analysis of two phase 2 trials
- **1003O. Phase I study** of GCC CAR-T therapy in patients with advanced colorectal cancer
- **LBA1. INTerpath-001**: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
- **LBA2 - Perioperative durvalumab** with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial
- **2616RO**. A phase 2 study of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer (NSCLC)

https://www.sitcancer.org/blogs/thomas-martin/2026/10/28/2026-esmo-congress-scientific-highlights-oct-24?_zs=8KHKg&_zl=ukhA5

SELECTED PUBLICATIONS




CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer

Chen et al., 2026

DOI: 10.1016/j.cell.2026.07.016

Immune aging weakens T cell response to tumors and affects cancer treatment. Key factors causing T cell dysfunction in older tumors are still unclear. Researchers used single-cell CRISPR screens to identify Dusp5 and Zfp219 as important for CD8+ T cell function in aging. Losing Dusp5 boosts T cell growth, while Zfp219 deletion improves immune response by enhancing toxic molecule levels. Higher levels of ZNF219 in T cells from older patients relate to poorer treatment outcomes.



Targeting protein arginine methyltransferases to enhance cancer immunotherapy

Srour et al., 2026

DOI: 10.1016/j.chembiol.2026.09.010

Arginine methylation is a modification on many proteins that affects their interactions and regulates various cellular processes, such as RNA metabolism and immune responses. This text discusses new findings about arginine methylation's role in lowering tumor visibility to the immune system. It also covers the use of PRMT inhibitors and degraders in cancer treatment to improve immunotherapy results.



Chronic cigarette smoke exposure induces distinct stem cell states driving genetic driver-specific non-small cell lung cancer subtypes

Wang et al., 2026

DOI :10.1073/pnas.2604393123

Cigarette smoke causes chronic inflammation that helps develop non-small cell lung cancer (NSCLC) by affecting genes. Research using normal lung organoids shows that chronic exposure to cigarette smoke leads to two types of stem cells evolving into premalignant states without major mutations. This process leads to an immune evasion state where certain death signals are reduced due to the silencing of a specific gene, Zbp1. The stem cell types respond differently to mutations in the Kras and Tp53 genes, resulting in two NSCLC types..

SELECTED PUBLICATIONS




Altered sperm DNA methylation provides an epigenetic route from overweight and older men to intergenerational disease transmission

Mathieu Schulz et al., 2026

DOI :10.1073/pnas.2534171123

Childhood neurodevelopmental disorders are becoming more common, but we know little about how they are inherited. Studies show that higher paternal Body Mass Index (BMI) and age may increase the risk of these disorders in children. The way genes are expressed can be affected by environmental factors, diet, and lifestyle, but it's unclear if a man's BMI and age change the sperm methylome and affect child development.



A muscle-enriched mitochondrial protein regulates postnatal heart growth through mitonuclear ubiquinone–PPAR signaling

Kentaro Hirose et al., 2026

DOI: 10.1073/pnas.2619615123

Mitochondria are important for energy production, but many mitochondrial proteins have specific roles in different tissues. This study identifies Coenzyme Q10a (Coq10a) as a key factor in heart growth after birth. Deficiency in Coq10a leads to abnormal heart growth and changes in intracellular ubiquinone levels without affecting energy production.



A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir

Alexander Uhrig et al., 2026

DOI : 10.1038/s41591-026-04663-5

Clinical data on Bundibugyo virus (BDBV) infection is limited, and there is no approved virus-specific treatment. This report describes a 39-year-old healthcare worker who contracted BDBV in Ituri Province, Democratic Republic of the Congo, and was evacuated to Germany. He received an investigational treatment, MBP134, along with remdesivir and supportive care. Viral RNA was highest in throat swabs and plasma, becoming undetectable by day 13 and in semen by day 25. The patient showed evidence of immune responses and recovered, being

SELECTED PUBLICATIONS




Dysregulated adult hippocampal neurogenesis in major depressive disorder

Madeleine S. Peng et al., 2026

DOI: 10.1038/s41591-026-04571-8

Major depressive disorder (MDD) is linked to smaller hippocampal size, altered brain connections, and negative memory, indicating problems with hippocampal plasticity. This study looked at the molecular causes of hippocampal issues in nonmedicated MDD individuals by examining neurogenic pathways and gene expression. It found that a neurogenic process is stalled in MDD, linked to stress responses and changes in gene activation.




Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment

Kristen S. Young and Sean W. Fanning, 2026

DOI:10.1172/JCI207633.

One in eight women will be diagnosed with breast cancer. Most of these cancers depend on estrogen receptor α (ERα) for growth and spread. Selective estrogen receptor degraders (SERDs) like fulvestrant are used as second-line treatments for advanced cases. Some tumors with mutations in the ESR1 gene still respond to fulvestrant but need higher doses.



XY0206 targets FLT3-dependent resistance states in acute myeloid leukemia

Shen et al., 2026

DOI : 10.1172/JCI20470

Activating mutations in the FLT3 gene cause aggressive acute myeloid leukemia (AML) with a poor outlook. FLT3 inhibitors help, but there are resistance issues. XY0206, a modified sunitinib, effectively targets FLT3 and kills AML cells with FLT3-ITD. In trials, it achieved a 45.7% complete remission rate, especially 60.0% in FLT3-ITD patients, indicating potential for further research.

RECOMMENDED EVENTS & STUDENTSHIP

Cancer Research UK-Manchester Institute

PhD Student Recruitment 2027 – Now Open

Applications are now open for our 2027 PhD Student intake – apply before the **deadline of Friday 6th November 1700 GMT**

CRUK is pleased to announce six exciting postgraduate opportunities within the Cancer Research UK Manchester Institute for intake in 2027!

https://www.cruk.manchester.ac.uk/phd-student-recruitment-2027/

The RAMP-UP Doctoral Programme

Researchers from Lunds universitet, Leiden University Medical Center, DTU - Technical University of Denmark and Hannover Medical School are invited to submit interdisciplinary PhD project proposals in regenerative medicine and advanced therapy medicinal products

Call open: 15 October – 15 November 2026

https://www.stemcellcenter.lu.se/RAMP-UP/call-2-research-projects

Applications for our 2027 sandwich student programme are now open.

- access to well-resourced research labs and state-of-the-art facilities
- a 12-month full-time (36 hours/week) contract as a Sandwich Placement Laboratory Research Assistant
- a salary of £28,910 per annum to cover living and travel costs during the placement

Apply by 6 October 2026

https://www.crick.ac.uk/careers-and-study/students/sandwich-students

RECOMMENDED EVENTS & STUDENTSHIP



AACR Annual Meeting 2027
Registration and abstract submission are now open for the AACR Annual Meeting 2027, themed Delivering Discovery Science: The Bridge to Breakthrough Therapeutics
April 2-7, 2027 • Orange County Convention Center • Orlando, FL
https://www.aacr.org/meeting/aacr-annual-meeting-2027/registration/



NOSTER & Science Microbiome Prize: Submissions Are Open
It is open to investigators who received their M.D., Ph.D., or M.D./Ph.D. in the last ten years.
The first prize includes a US$25,000 cash award, and your winning essay published in Science!
https://www.science.org/content/prize-award/noster-and-science-microbiome-prize?utm_medium=email&utm_source=publishing-sfmc&utm_campaign=noster27&utm_content=email&utm_id=recVMD0halrO7pVcP&et_rid=51389519&et_cid=6101074



Protein Sciences 2026 is built for two days of exceptional science, from AI-driven protein modelling to producing the hardest-to-make targets, with speakers from academia and tool providers sitting side by side and time to ask questions after every talk. As always, it's free to attend.
https://elrig.eventsair.com/protein-sciences-in-drug-discovery-2026/delegate-registration/Site/Register?utm_source=Master+List&utm_campaign=47a2b86447-EMAIL_CAMPAIGN_2026_03_31_02_58_COPY_01&utm_medium=email&utm_term=0_-e140d5b44e-113230101

Your BIOSCITECH Newsletter : 1 November 2026

FOLLOW US

https://www.linkedin.com/company/102551429/admin/page-posts/published/

Do Not Miss Your Next Free Issue
Thank You ☺



Produced by Dr. Mohamed Boudjelal ,
mohamed-boudjelal-mba-ph-d-bb06232/

BioSciTech biweekly NEWS